Accessory Pathway Antegrade Effective Refractory Period Among WPW Patients: the Risk in Relation to the Location

Accessory Pathway Antegrade Effective Refractory Period Among Wolff Parkinson White Patients: the Risk in Relation to the Location

To correlate the antegrade effective refractory period of the accessory pathway with its anatomical location in the heart.

To investigate whether the accessory pathway location can predict the high risk nature of the accessory pathway

Study Overview

• Status: Not yet recruiting
• Conditions: Wolff-Parkinson-White Syndrome
• Intervention / Treatment: Procedure: electrophysiological study

Detailed Description

The Wolf-Parkinson-White (WPW) syndrome is a clinical entity characterized by the presence of ≥1 accessory pathways between the atria and the ventricles pre-disposing patients to arrhythmias. Anterograde conduction through the accessory pathway leads to preexcitation of the ventricles and a delta wave in the ECG. The prevalence of preexcitation in the general population has been estimated to be 1 to 3 in 1000 individuals. Although most asymptomatic patients with pre-excitation have a good prognosis, there is also a lifetime risk of malignant arrhythmias and SCD, estimated to be 0.1 % per patient year.

• More worrisome is the fact that this event can be the first manifestation of the disease in up to 53 % of patients.
• Atrial fibrillation (AF) can be a life-threatening arrhythmia in the WPW syndrome if the AV AP has a short anterograde refractory period (RP), allowing too many atrial impulses to be conducted to the ventricle.
• This will result in very high ventricular rates with possible deterioration into ventricular fibrillation (VF) and sudden death.
• Parameters proved to indicate high risk AP include AP effective refractory period <240 ms, shortest preexcited RR interval <250 ms
• Certain Locations were thought to be associated with higher risk of the accessory pathway like Septal localization which was significantly more frequent in patients with VF when compared with individuals with no VF but the overall number of patients is limited . .

These debatable relations between AP location and its risk stratification was not extensively studied in larger scale studies….

• Study Type: Observational
• Enrollment (Anticipated): 35

Contacts and Locations

• Study Contact: Name: M K Ibrahim, Msc; Phone Number: +20 1152453334; Email: mohamed011354@med.au.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Wolff Parkinson White patients

Description

1. Inclusion criteria:

   all patients with WPW admitted to Assuit university hospital and subjected to invasive EPS

2. Exclusion criteria:

   1. heart failure
   2. cardiomyopathy

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Wolff Parkinson White patients; The investigators will decide the location of the AP by: - Invasively: if the patient is subjected to (EPS) • There are different locations of AP To assess whether the AP is of high risk or not, for all patients the Antegrade refractory period of the APAERP of the AP will be determined by one of the following ways: ( AERP) is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval (SPERRI) during spontaneous or induced AF. The AERP and the risk category of the AP according to its value, will be recorded in relation to the site of the AP determined in every case and compared between different accessory Locations to see whether some of these positions are more liable to be of higher risk or there is no differerence between different positions.

Procedure: electrophysiological study; To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways: The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study.. The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP. The shortest pre-excited R-R interval during spontaneous or induced AF.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the antegrade refractory period during invasive EPS done for the patients	the values will be correlated to the site of the AP diagnosed be EPS.. according to the previous studies and the current guidelines, if the refractory period is < 250 ms, this is considered a high risk AP	2 hours

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Principal Investigator: M K Ibrahim, Msc, Assiut University; Study Director: S S Atta, Professor, Assiut University; Study Director: S M Taha, Lecturer, Assiut University

Study record dates

Study Major Dates

• Study Start (Anticipated): March 1, 2020
• Primary Completion (Anticipated): March 1, 2022
• Study Completion (Anticipated): March 1, 2023

Study Registration Dates

• First Submitted: September 25, 2019
• First Submitted That Met QC Criteria: September 25, 2019
• First Posted (Actual): September 27, 2019

Study Record Updates

• Last Update Posted (Actual): January 30, 2020
• Last Update Submitted That Met QC Criteria: January 28, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: Wolff-Parkinson-White Syndrome
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Congenital Abnormalities; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Pathological Conditions, Anatomical; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Heart Defects, Congenital; Cardiovascular Abnormalities; Parkinson Disease; Pre-Excitation Syndromes; Wolff-Parkinson-White Syndrome; Accessory Atrioventricular Bundle
• Other Study ID Numbers: WPW syndrome

Plan for Individual participant data (IPD)

Study Data/Documents

1. Pubmed

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No